Welcome to our dedicated page for M3 news (Ticker: MTHRY), a resource for investors and traders seeking the latest updates and insights on M3 stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect M3's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of M3's position in the market.
Summary not available.
M3 Wake Research has appointed Lucian Cappoli as the new Head of Early Development and Phase I Operations, effective March 7, 2023. Cappoli, who has extensive experience in Phase I clinical research, aims to enhance the capabilities of their Phase I research sites and expand operations across the network. The Raleigh site, operational since 2012, will serve as a cornerstone for this growth. Cappoli expressed enthusiasm for performing early-phase studies, focusing on safety and efficacy to expedite drug delivery to patients. This move positions M3 Wake Research to capitalize on the expanding clinical trial market.
M3 Wake Research has announced the acquisition of Multi-specialty Research Associates (MSRA) located in Lake City, Florida. This strategic move expands Wake Research's operations into a new state, enhancing its national footprint of 23 clinical research sites across eight states. The acquisition is aimed at improving access to diverse clinical trials, particularly in women's health, vaccines, and primary care, while leveraging MSRA's established reputation and expertise in clinical research. Financial details of the transaction remain undisclosed.
Wake Research, a leading clinical trial network, was recognized as a Top Enroller by Novavax for their COVID-19 Phase III vaccine trial, enrolling over 2,000 patients. Since the start of Operation Warp Speed, they have contributed significantly to vaccine data. The Novavax vaccine shows promise, with U.K. trials indicating 89.3% efficacy. The vaccine's distribution is simplified due to its non-mRNA formulation. Additionally, Wake Research was featured as a Top CRO Service Company of 2021 by PharmaTech Outlook due to their impactful work in clinical research.